Immune cells can be trained to respond faster to future threats
Out of Stanford's laboratories comes a quietly radical idea: rather than teaching the immune system to recognize a specific enemy, what if we simply kept the body's first line of defense perpetually ready for battle? A nasal spray tested in rats has shown the capacity to prime lung immunity against flu, COVID-19, bacteria, and allergens alike — not by memorizing a pathogen's face, but by awakening the ancient, generalist sentinels that stand watch before any specific threat is named. It is a promising early chapter in a longer story, one that scientists caution will take years yet to fully tell.
- A single nasal spray protected rats against flu, COVID-19, bacteria, and allergens simultaneously — a breadth no conventional vaccine has attempted.
- The core tension is biological: viruses mutate constantly, rendering targeted vaccines obsolete year after year and exposing the world's fragility to novel respiratory threats.
- Stanford's approach sidesteps the mutation problem entirely by activating the innate immune system — the lungs' non-specific early-warning network — rather than training recognition of any particular viral protein.
- Multiple competing strategies are now in motion globally, from AI-designed vaccines to intranasal flu candidates in advanced trials, all racing toward broader, longer-lasting respiratory protection.
- Human trials for the Stanford spray are being planned, but experts are clear: a truly universal respiratory vaccine ready for widespread use remains years, not months, away.
Researchers at Stanford have developed a nasal spray that, in rat trials spanning three months, strengthened lung immunity against flu, COVID-19, respiratory bacteria, and seasonal allergens — all from a single application. The approach marks a conceptual departure from conventional vaccine design. Rather than training the immune system to recognize specific viral proteins, it activates the innate immune system: the body's generalist, first-response defense layer.
The idea traces back to earlier work on the BCG tuberculosis vaccine, which was found to prompt T cells to migrate into the lungs and keep innate immune cells in a sustained state of readiness. The new spray applies the same logic using two adjuvants that recruit T cells into lung tissue, where they emit chemical signals mimicking infection cues — leaving the immune system primed to intercept pathogens before they gain a foothold.
The deeper challenge the spray is designed to circumvent is viral mutation. Flu viruses and coronaviruses change continuously, which is why annual vaccine updates are necessary and why novel pathogens can outpace existing immunizations so quickly. The COVID-19 pandemic sharpened this vulnerability into urgent focus, accelerating a global search for broader solutions.
Other approaches are advancing in parallel: NIH's FluMos-v2 targets hemagglutinin proteins from six flu strains and has completed early human trials; an intranasal flu vaccine using whole inactivated viruses is in more advanced clinical testing; pan-coronavirus vaccines and AI-designed candidates targeting slow-mutating protein regions are also in development. The Stanford spray stands apart by addressing viruses, bacteria, and allergens together, without targeting any single pathogen.
Human trials are being planned, and if the results hold, the implications for respiratory medicine could be significant — a shift from annual, pathogen-specific updates toward durable, broad-spectrum lung defense. For now, though, experts are measured: the distance between a promising rat model and a vaccine ready for the world remains considerable.
Researchers at Stanford have developed a nasal spray that, when tested in rats over three months, strengthened lung immunity against flu viruses, COVID-19, bacteria that invade the respiratory tract, and seasonal allergens—all through a single application. The work represents a significant shift in how scientists think about vaccine design, moving away from the traditional approach of training the immune system to recognize specific viral proteins and instead activating the body's first line of defense: the innate immune system.
The concept emerged from earlier research on the BCG vaccine, which prevents tuberculosis. In 2023, Bali Pulendran, a pathologist at Stanford, and his colleagues discovered that rats receiving BCG developed T cells that migrated to the lungs, where they released chemical signals that kept innate immune cells active for months. Those animals were subsequently protected against both COVID-19 and flu. The new spray works on a similar principle. It combines two adjuvants—substances that trigger an immune response—to activate T cells and draw them into the lungs. Once there, these T cells emit chemical signals that mimic natural infection cues, keeping the lung's innate immune cells in a heightened state of readiness. If a pathogen enters the lungs, the immune system is already primed to stop the infection before it takes hold.
Yet the path from promising animal studies to a vaccine that actually works in humans remains long. Experts told Live Science that while the February publication in Science is encouraging, a truly universal respiratory vaccine is still years away. The fundamental challenge is viral mutation. Flu viruses and coronaviruses constantly change—sometimes in small ways, sometimes dramatically—which is why flu shots and COVID-19 boosters need updating every year. Alfredo Mena Lora, director of infection control at Saint Anthony Hospital in Chicago, explained that as viruses circulate, they mutate in both large and small ways, making previously effective vaccines obsolete.
The COVID-19 pandemic accelerated the push for universal vaccines by exposing how vulnerable the world is to novel respiratory pathogens and how quickly existing vaccines become outdated. Since then, researchers have pursued multiple strategies. Many focus on targeting parts of viruses that change slowly across different strains. For flu, scientists are zeroing in on the hemagglutinin protein that protrudes from the viral surface, but specifically the "stem" rather than the "head," because the stem mutates more slowly. The NIH's FluMos-v2, which targets hemagglutinin from six flu strains, recently completed early-phase human trials and generated encouraging immune responses. Another intranasal flu vaccine in more advanced clinical trials uses whole inactivated viruses to stimulate antibody production and T cells that attack infected cells—an approach that could provide broad protection against multiple flu strains and potentially block transmission, something current flu vaccines do not do.
Other teams are developing pan-coronavirus vaccines to protect against current and future coronaviruses, while some are exploring vaccines designed with artificial intelligence, using computational tools to identify viral protein regions that mutate slowly and appear across many viruses. The Stanford spray is distinctive because it targets viruses, bacteria, and allergens simultaneously rather than focusing on a single pathogen family. Unlike traditional vaccines, it does not teach the immune system to recognize specific proteins from a particular antigen. Instead, it activates the innate immune system—the early-warning system in the lungs that can detect and respond quickly to a wide range of pathogens, even ones the body has never encountered before. Pulendran told Live Science that these lung cells are the first to detect infection and help determine how the broader immune response unfolds, and that research over the past decade has shown that innate immune cells can be "trained" to respond faster and more effectively to future threats.
The team is now preparing early-phase human trials. If successful, the approach could reshape how we think about respiratory protection—moving from annual updates for specific viruses to a more durable, broad-spectrum defense. But the gap between a working rat model and a vaccine ready for widespread human use remains substantial, and experts caution against expecting a true universal respiratory vaccine anytime soon.
Notable Quotes
As viruses circulate, they mutate in both large and small ways— Alfredo Mena Lora, director of infection control at Saint Anthony Hospital in Chicago
Innate immune cells can be trained to respond faster and more effectively to future threats— Bali Pulendran, pathologist at Stanford University
The Hearth Conversation Another angle on the story
So the spray doesn't work like a traditional vaccine at all—it's not teaching the immune system to recognize a specific virus?
Exactly. Traditional vaccines show your immune system what a particular virus looks like so it can make antibodies against it. This spray does something different. It wakes up the immune cells that are already sitting in your lungs, telling them to stay alert and ready to fight anything that comes in.
But if it's not targeting specific viruses, how does it protect against flu and COVID-19 and bacteria all at once?
Because the innate immune system doesn't work by recognition—it works by pattern detection. It can sense when something is wrong, when there's an infection happening, regardless of what the pathogen is. The spray essentially puts those cells on high alert.
That sounds almost too broad. What's the catch?
The catch is that we don't yet know if it works in humans the way it works in rats. And even if it does, viruses keep mutating. The spray might buy us time, but it's not a permanent solution to the mutation problem.
So why are scientists so excited about it if it's not the final answer?
Because it's a different angle on the problem. Instead of chasing every new variant with a new vaccine formula, you're strengthening the body's general defense system. That's potentially more durable, even if it's not perfect.
When could people actually use this?
The team is moving into early human trials now, but realistically, if everything goes well, you're looking at years before it's available to the public. And that's assuming it works as well in people as it did in rats.